The role of the dorsal raphe-serotonergic system and cholinergic receptors in the modulation of working memory.
The present study investigated the role of the dorsal raphe-serotonergic system and its interaction with muscarinic or nicotinic receptors in the modulation of working memory and motor activity by assessing the effects of serotonin lesion with pCA and cholinergic receptor blockade on the performance of rats in a working memory (delayed non-matching to position, DNMTP) task. The pCA lesion did not impair the choice accuracy or motor activity of rats in the DNMTP-task. The lower dose of scopolamine (0.075 mg/kg) impaired percent correct responses already at the shortest delay which is not indicative of a working memory impairment per se. Scopolamine also disrupted motor activity markedly. The effects of scopolamine 0.075 mg/kg on the choice accuracy were aggravated by pCA treatment. Furthermore, the effects of N-methylscopolamine (0.150 mg/kg) were comparable with scopolamine. The higher dose of mecamylamine (3.0 mg/kg) also interfered with motor activity and it decreased the choice accuracy. The performance disruption induced by mecamylamine was not as severe as that seen with scopolamine. Mecamylamine did not reveal any interaction with the serotonergic lesion. Hexamethonium slightly decreased the percent correct responses, while not interfering with motor activity of rats. The present results suggest that: (i) lesion of serotonergic fibers with pCA does not significantly impair the choice accuracy or interfere with motor activity of rats; (ii) the blockade of cholinergic receptors does not impair working memory per se, but disrupts motor activity, and (iii) pCA lesion of serotonergic fibers aggravates the non-mnemonic choice accuracy impairment induced by central muscarinic blockade, while not interacting with the cholinolytics in modulation of motor activity.
Ruotsalainen
S
S
A.I. Virtanen Institute, University of Kuopio, Finland.
Miettinen
R
R
MacDonald
E
E
Riekkinen
M
M
Sirviö
J
J
D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism; D018680:Cholinergic Antagonists / Q000494:pharmacology; D010134:Fenclonine / Q000633:toxicity; D006584:Hexamethonium Compounds / Q000494:pharmacology; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology; D008570:Memory, Short-Term / Q000187:drug effects / Q000502:physiology*; D018727:Muscarinic Antagonists / Q000494:pharmacology; D018733:Nicotinic Antagonists / Q000494:pharmacology; D011903:Raphe Nuclei / Q000378:metabolism / Q000473:pathology / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D012601:Scopolamine / Q000494:pharmacology; D012701:Serotonin / Q000502:physiology*
D015306:Biogenic Monoamines; D018680:Cholinergic Antagonists; D006584:Hexamethonium Compounds; D018727:Muscarinic Antagonists; D018733:Nicotinic Antagonists; D011950:Receptors, Cholinergic; D012701:Serotonin; D008464:Mecamylamine; D012601:Scopolamine; D010134:Fenclonine